Tyrosine kinase inhibitor research presses on despite halted clinical trial.
Garber
K
K
D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D015507:Drugs, Investigational / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D016391:Genes, src / Q000235:genetics; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000187:drug effects / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000187:drug effects / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000187:drug effects / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor; D015398:Signal Transduction / Q000187:drug effects
D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D007211:Indoles; D010982:Platelet-Derived Growth Factor; D011758:Pyrroles; D017978:Receptors, Growth Factor; C116890:Semaxinib; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor